NKX2-1 and cancer: The latter is of direct clinical relevance and translates into better survival for NKX2–1 overexpressing cancer patients receiving etoposide-based treatments and emphasizes novel future treatment perspectives for NKX2–1-positive cancers with more specificity and less toxicity using sertraline.